Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia

B Cell ◽

Lymphoblastic Leukemia ◽

Cell Precursor ◽

Inotuzumab Ozogamicin ◽

Drug Conjugate

PCN118 Budget IMPACT Analysis of Inotuzumab Ozogamicin for the Treatment of Adults with Relapsed or Refractory B-Cell Precursor ACUTE Lymphoblastic Leukemia in the Netherlands

Value in Health ◽

10.1016/j.jval.2020.08.255 ◽

2020 ◽

Vol 23 ◽

pp. S444

Author(s):

I. van Oostrum ◽

K. De Lameillieure ◽

T.A. Russell-Smith

Keyword(s):

The Netherlands ◽

B Cell ◽

Impact Analysis ◽

Budget Impact ◽

Lymphoblastic Leukemia ◽

Budget Impact Analysis ◽

Cell Precursor ◽

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States

PharmacoEconomics ◽

10.1007/s40273-019-00812-6 ◽

2019 ◽

Vol 37 (9) ◽

pp. 1177-1193 ◽

Cited By ~ 6

Author(s):

Thomas E. Delea ◽

Xinke Zhang ◽

Jordan Amdahl ◽

Diana Boyko ◽

Franziska Dirnberger ◽

...

Keyword(s):

United States ◽

Cost Effectiveness ◽

B Cell ◽

Lymphoblastic Leukemia ◽

The United States ◽

Adult Patients ◽

Cell Precursor ◽

Use of inotuzumab-ozogamicin in a child with Down syndrome and refractory B-cell precursor acute lymphoblastic leukemia

Pediatric Blood & Cancer ◽

10.1002/pbc.27562 ◽

2018 ◽

Vol 66 (4) ◽

pp. e27562 ◽

Cited By ~ 2

Author(s):

Laura Murillo ◽

José Luis Dapena ◽

Pablo Velasco ◽

Cristina Díaz de Heredia

Keyword(s):

Down Syndrome ◽

B Cell ◽

Lymphoblastic Leukemia ◽

Cell Precursor ◽

PCN142 - COST-EFFECTIVENESS ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA

Value in Health ◽

10.1016/j.jval.2018.09.225 ◽

2018 ◽

Vol 21 ◽

pp. S38

Author(s):

S. Djambazov ◽

G. Slavchev ◽

M. Encheva-Malinova ◽

V. Varbanova ◽

M. Velchev ◽

...

Keyword(s):

Cost Effectiveness ◽

B Cell ◽

Lymphoblastic Leukemia ◽

Cost Effectiveness Analysis ◽

Cell Precursor ◽

Inotuzumab Ozogamicin ◽

Effectiveness Analysis

PCN71 - BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA

Value in Health ◽

10.1016/j.jval.2018.09.153 ◽

2018 ◽

Vol 21 ◽

pp. S26

Author(s):

S. Djambazov ◽

G. Slavchev ◽

M. Encheva-Malinova ◽

Y. Pavlova ◽

V. Varbanova ◽

...

Keyword(s):

B Cell ◽

Impact Analysis ◽

Budget Impact ◽

Lymphoblastic Leukemia ◽

Budget Impact Analysis ◽

Cell Precursor ◽

Decision letter for "High prevalence of MEF2D fusion in human B‐cell precursor acute lymphoblastic leukemia cell lines"

10.1002/hon.2762/v3/decision1 ◽

2020 ◽

Keyword(s):

B Cell ◽

Cell Lines ◽

Lymphoblastic Leukemia ◽

Leukemia Cell ◽

Cell Precursor ◽

Leukemia Cell Lines ◽

High Prevalence ◽

Human B Cell

Decision letter for "High prevalence of MEF2D fusion in human B‐cell precursor acute lymphoblastic leukemia cell lines"

10.1002/hon.2762/v1/decision1 ◽

2020 ◽

Keyword(s):

B Cell ◽

Cell Lines ◽

Lymphoblastic Leukemia ◽

Leukemia Cell ◽

Cell Precursor ◽

Leukemia Cell Lines ◽

High Prevalence ◽

Human B Cell

Faculty Opinions recommendation of IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725540965.793524754 ◽

2016 ◽

Author(s):

Jan Starý

Keyword(s):

Maintenance Therapy ◽

B Cell ◽

Prognostic Marker ◽

Lymphoblastic Leukemia ◽

Cell Precursor ◽

Independent Prognostic Marker ◽

Leukemia Group

Faculty Opinions recommendation of Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726364889.793551058 ◽

2018 ◽

Author(s):

Jan Starý

Keyword(s):

B Cell ◽

Lymphoblastic Leukemia ◽

Cell Precursor

Low EVI1 expression at diagnosis predicted poor outcomes in pediatric Ph-negative B cell precursor acute lymphoblastic leukemia patients

Pediatric Hematology and Oncology ◽

10.1080/08880018.2021.1939818 ◽

2021 ◽

pp. 1-11

Author(s):

Lu Yang ◽

Feng-Ting Dao ◽

Ai-Dong Lu ◽

Wen-Min Chen ◽

Ling-Di Li ◽

...

Keyword(s):

B Cell ◽

Lymphoblastic Leukemia ◽

Cell Precursor ◽

Poor Outcomes